

REMARKS

Claims 1-3, 6-11, 13, and 14 were pending in the present application. Claims 1-3, 7, 8, 13, and 14 have been canceled herein without prejudice to their presentation in another application. Claims 6, 10, and 11 have been amended herein. New claims 15-20 have been added herein. No new matter has been added. Upon entry of the present amendment, claims 6, 9-11, and 15-20 will be pending.

Applicant thanks the Examiner for indicating that claims 6, 9, and 11 “would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims” (see, Office Action at page 3). As suggested by the Examiner, Applicant has amended claim 6 to incorporate the features of claim 1, from which it had previously depended. Claim 9 requires no amendment as it is already in independent form. Finally, claim 11 has been amended to also incorporate the features of claim 1, from which it had previously depended.

Applicant has canceled rejected claims 1-3, 7, 8, 13, and 14 herein without prejudice to their presentation in another application.

Applicant has also amended claim 10, reciting a pharmaceutical formulation, to be dependent upon presently amended claim 6.

New claims 15-20 have also been added herein. Each of these new claims finds support, for example, in the canceled compound claims. The recited subject matter of the canceled compounds claims has been introduced into the new method claims, which are dependent upon claim 11. As stated above, claim 11 has been indicated as being allowable.

I. The Claimed Invention Is Not Obvious

Claims 1-3, 7, 8, 10, 13, and 14 are rejected under 35 U.S.C. §103(a) as allegedly being unpatentable over the combination of U.S. Patent No. 5,922,767 (hereinafter, the “Kanamaru reference”) and U.S. Patent No. Patani et al., Chem. Rev., 1996, 3147-3176 (hereinafter, the “Patani reference”). Although Applicant disagrees with the reasoning set forth in the Office Action, solely to advance prosecution of the claimed invention, claims 1-3, 7, 8, 13, and 14 have been canceled herein. As stated above, claim 10 has been amended herein to be dependent on

allowable claim 6. Thus, the rejection is now moot. Accordingly, Applicant respectfully requests that the rejection under 35 U.S.C. §103(a) be withdrawn.

II. Conclusion

In view of the foregoing, Applicant respectfully submits that the claims are in condition for allowance. An early notice of the same is earnestly solicited. The Office is invited to contact Applicant's undersigned representative at (610) 640-7859 if there are any questions regarding Applicant's claimed invention.

The Commissioner is hereby authorized to debit any underpayment of fee due or credit any overpayment to Deposit Account No. 50-0436.

Respectfully submitted,

/Paul K. Legaard, Reg.# 38534/
Paul K. Legaard, Ph.D.

Date: **9 September 2008**

Pepper Hamilton LLP
400 Berwyn Park
899 Cassatt Road
Berwyn, PA 19312-1183

Telephone: 610.640.7859
Facsimile: 267.430.7647